Single-Arm, Phase II Proof of Concept Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- 28 May 2019 Planned End Date changed from 1 Jul 2021 to 30 Apr 2021.
- 28 May 2019 Planned primary completion date changed from 1 Jul 2020 to 30 Apr 2020.
- 28 May 2019 Planned initiation date changed from 1 Jul 2018 to 31 Jul 2019.